The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）

• Status: Recruiting
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the optimal intervention time of radiotherapy for oligometastatic stage iv lung cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sichuan Cancer Hospital and Research Institute
• Collaborators: Cancer Hospital of Guizhou Province; Mianyang Central Hospital
• Treatments: Cisplatin; Docetaxel; Pemetrexed

Criteria

Inclusion Criteria:

• 18 to 75 years old , male or female

• Pathologically or cytologically proven oligometastatic stage IV NSCLC non-small cell lung cancer（NSCLC）

• Primary tumors can be measured

• Distant organ metastases number ≤ 5

• Karnofsky score >70,Zubrod performance status 0-1

• Estimated life expectancy of at least 12 weeks

• reproductive age women should ensure that before entering the study period contraception

• Hemoglobin≥10.0g/dL,WBC≥ 4000 cells/mm³,Platelet count≥100,000 cells/mm³

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal,bilirubin normal

• Creatinine normal OR creatinine clearance ≥ 60 mL/min

• Patients have good compliance to treatment and follow-up of acceptance.

Exclusion Criteria:

• Allergic to pemetrexed, cisplatin, docetaxel and contrast medium

• Distant metastases organs > 5

• The primary tumor or lymph node already received surgical treatment (except for biopsy)

• Patient who received radiotherapy for primary tumor or lymph node

• Patient who received the the epidermal growth factor targeted therapy

• Patient who received chemotherapy or immunotherapy

• Patient who suffered from other malignant tumor

• Patient who have taken other drug test within 1 month

• Pregnant woman or Lactating Women and Women in productive age who refuse to take contraception in observation period

• Subject with a severe allergic history or idiosyncratic

• Subject with severe pulmonary and cardiopathic disease history

• Refuse or incapable to sign the informed consent form of participating this trial

• Drug abuse or alcohol addicted

• Subject with a Personality or psychiatric diseases, people with no legal capacity or people with limited capacity for civil conduct